Picture loading failed.

Pre-Made Sugemalimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sugemalimab is an investigational anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody. It mimics the natural G-type immunoglobulin 4 human antibody, which lowers immunogenicity and possible toxicity risks.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-534-1mg 1mg 3090
GMP-Bios-ab-534-10mg 10mg Inquiry
GMP-Bios-ab-534-100mg 100mg Inquiry
GMP-Bios-ab-534-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Sugemalimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
INN Name Sugemalimab
TargetCD274
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCLambda
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesCstone Pharmaceuticals
Conditions Approvedna
Conditions ActiveCancers;Non-small Cell Lung Cancer;T-cell Lymphoma;Solid tumours;Hodgkin Lymphoma;Gastric cancer
Conditions Discontinuedna
Development Techna